Frederick Mohr
Geen lopende functies
Profiel
Frederick Stephen Mohr worked as a Director at ZS Pharma, Inc., Chief Compliance Officer at AstraZeneca PLC, Vice President & Senior Counsel at Bristol-Myers Squibb Holdings Ltd., and General Counsel at Sio Gene Therapies, Inc. He received an undergraduate degree from Yale University and a graduate degree from the University of Virginia School of Law.
Eerdere bekende functies van Frederick Mohr
| Bedrijven | Functie | Einde |
|---|---|---|
| ZS PHARMA INC | Directeur/Bestuurslid | - |
Bristol-Myers Squibb Holdings Ltd.
 Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The company is based in Uxbridge, UK. | Corporate Officer/Principal | - |
| ASTRAZENECA PLC | Compliance Officer | - |
| SIO GENE THERAPIES INC. | Algemeen Adviseur | - |
Opleiding van Frederick Mohr
| Yale University | Undergraduate Degree |
| University of Virginia School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Bristol-Myers Squibb Holdings Ltd.
Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The company is based in Uxbridge, UK. | Miscellaneous |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
